Processing your request


please wait...

 | Case Page

 | Case Page |

Case Page

 

Endocyte, Inc.

Case Summary

Endocyte, Inc. Securities Litigation

Case Summary

Case Status:    DISMISSED    
On or around 12/17/2019 (Notice of voluntarily dismissal)

Filing Date: November 08, 2018

Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer.

On October 18, 2018, Endocyte issued a press release to announce the Proposed Merger between Endocyte and Novartis AG.

The Complaint alleges that on October 31, 2018, the Board authorized the filing of a materially incomplete and misleading preliminary proxy statement (the “Proxy”) with the Securities and Exchange Commission (“SEC”), in violation of Sections 14(a) and 20(a) of the Exchange Act.

This case was voluntarily dismissed as moot on December 17, 2018.

Company & Securities Information

Defendant: Endocyte, Inc.

COMPANY INFORMATION:

Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States

SECURITIES INFORMATION:

Ticker Symbol: ECYT
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data


"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.

First Identified Complaint

George A. Lareau, et al. v. Endocyte, Inc., et al.

COURT: S.D. New York
DOCKET #: 18-CV-10392
JUDGE: Hon. Jesse M. Furman
DATE FILED: 11/08/2018
CLASS PERIOD START: 10/18/2018
CLASS PERIOD END: 11/08/2018
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Monteverde & Associates PC
    350 Fifth Avenue, 59th Floor, Monteverde & Associates PC, NY 10118
    (212) 971-1341 ·
First Identified Complaint (FIC) Filings:
No Document Title Filing Date
1 Class Action Complaint 11/08/2018
2 U.S. District Court Civil Docket 12/17/2018
3 Notice of Dismissal 12/17/2018

Reference Complaint

—Reference Complaint Complaint Related Data is not available

Related District Court Filings

No Document Title Filing Date
1 Complaint for Violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 11/06/2018
2 U.S. District Court Civil Docket 11/07/2018
 
 

Cases